Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label neoadjuvant sunitinib with radiotherapy in unresectable glioblastoma (RPA V–VI, biopsy only)
2008-006728-73Phase 2Terminated
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in glioblastoma (GBM), sponsored by Grupo Español de Investigación en Neurooncología. Primary endpoints: Objective response at 8 weeks and Treatment toxicity. Started Feb 2010; status: terminated.
02
Drugs
sunitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-006728-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006728-73.